Syngene has completed a payment of Rs. 158.2 crores on December 22, 2023 in addition to the initial payment of Rs. 395 crores made on December 1, 2023
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
The company is excited about the strategic progress that the company has made so far and are confident of delivering better business outcomes
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise
Both manufacturing facilities are based out of Benguluru, India
Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
He will be stationed at the company HQ in Bengaluru, India
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)